Citigroup’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.07M | Buy |
515,499
+162,164
| +46% | +$356K | ﹤0.01% | 3402 |
|
|
2026
Q1 | $862K | Sell |
353,335
-238,617
| -40% | -$478K | ﹤0.01% | 3218 |
|
|
2025
Q4 | $811K | Sell |
591,952
-2,147
| -0.4% | -$2.83K | ﹤0.01% | 3272 |
|
|
2025
Q3 | $737K | Sell |
594,099
-48,443
| -8% | -$57.8K | ﹤0.01% | 3364 |
|
|
2025
Q2 | $726K | Sell |
642,542
-45,982
| -7% | -$61.1K | ﹤0.01% | 3387 |
|
|
2025
Q1 | $1.01M | Sell |
688,524
-27,712
| -4% | -$52.2K | ﹤0.01% | 3260 |
|
|
2024
Q4 | $1.53M | Buy |
716,236
+246,926
| +53% | +$609K | ﹤0.01% | 3022 |
|
|
2024
Q3 | $1.31M | Buy |
469,310
+394,138
| +524% | +$1.05M | ﹤0.01% | 3034 |
|
|
2024
Q2 | $175K | Sell |
75,172
-603,057
| -89% | -$1.78M | ﹤0.01% | 3957 |
|
|
2024
Q1 | $3.03M | Buy |
678,229
+643,905
| +1,876% | +$2.69M | ﹤0.01% | 2081 |
|
|
2023
Q4 | $110K | Sell |
34,324
-304,432
| -90% | -$863K | ﹤0.01% | 4165 |
|
|
2023
Q3 | $1.07M | Buy |
338,756
+57,392
| +20% | +$252K | ﹤0.01% | 2445 |
|
|
2023
Q2 | $1.4M | Sell |
281,364
-273,979
| -49% | -$1.48M | ﹤0.01% | 2548 |
|
|
2023
Q1 | $2.74M | Buy |
555,343
+210,972
| +61% | +$1.35M | ﹤0.01% | 1812 |
|
|
2022
Q4 | $2.17M | Sell |
344,371
-113,418
| -25% | -$1.05M | ﹤0.01% | 1975 |
|
|
2022
Q3 | $4.94M | Buy |
457,789
+216,824
| +90% | +$2.95M | ﹤0.01% | 1573 |
|
|
2022
Q2 | $2.75M | Buy |
240,965
+121,800
| +102% | +$1.08M | ﹤0.01% | 1889 |
|
|
2022
Q1 | $1.09M | Sell |
119,165
-146,219
| -55% | -$1.52M | ﹤0.01% | 2886 |
|
|
2021
Q4 | $3.96M | Buy |
265,384
+138,729
| +110% | +$2.45M | ﹤0.01% | 2015 |
|
|
2021
Q3 | $3.25M | Sell |
126,655
-71,633
| -36% | -$1.7M | ﹤0.01% | 2111 |
|
|
2021
Q2 | $5.17M | Buy |
198,288
+74,327
| +60% | +$2.12M | ﹤0.01% | 1861 |
|
|
2021
Q1 | $4.38M | Buy |
123,961
+101,390
| +449% | +$3.42M | ﹤0.01% | 1878 |
|
|
2020
Q4 | $570K | Buy |
22,571
+11,806
| +110% | +$385K | ﹤0.01% | 4083 |
|
|
2020
Q3 | $406K | Sell |
10,765
-39,105
| -78% | -$1.47M | ﹤0.01% | 4034 |
|
|
2020
Q2 | $2.14M | Buy |
49,870
+4,254
| +9% | +$154K | ﹤0.01% | 2739 |
|
|
2020
Q1 | $887K | Buy |
45,616
+504
| +1% | +$12K | ﹤0.01% | 3304 |
|
|
2019
Q4 | $1.17M | Buy |
45,112
+2,733
| +6% | +$75.3K | ﹤0.01% | 3601 |
|
|
2019
Q3 | $1.16M | Sell |
42,379
-50,790
| -55% | -$1.45M | ﹤0.01% | 3484 |
|
|
2019
Q2 | $2.5M | Buy |
93,169
+89,284
| +2,298% | +$2.49M | ﹤0.01% | 2603 |
|
|
2019
Q1 | $112K | Sell |
3,885
-1,747
| -31% | -$50.7K | ﹤0.01% | 5628 |
|
|
2018
Q4 | $152K | Buy |
+5,632
| New | +$150K | ﹤0.01% | 5280 |
|
Other funds holding ALLO
P
FLSM
TGA
SCM
Citigroup's ALLO Position: Q2 2026 in Review
Citigroup increased its Allogene Therapeutics (ALLO) stake by 46% in Q2 2026, buying an estimated $356K and bringing the position to 515,499 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3402.
Citigroup first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.17M in Q2 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- Citigroup held 515,499 shares of Allogene Therapeutics worth $1.07M as of Q2 2026.
- Citigroup bought 162,164 Allogene Therapeutics shares in Q2 2026, an estimated $356K.
- Allogene Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3402 holding.
- Citigroup first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
- Citigroup's Allogene Therapeutics position peaked at $5.17M in Q2 2021.
- 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.